Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy

International Journal of Urology

Volumn 10, Issue 7, 2003, Pages 377-382

  Kitagawa, Yasuhide ^a   Koshida, Kiyoshi ^b   Mizokami, Atsushi ^b   Komatsu, Kazuto ^b   Nakashima, Shinichi ^c   Misaki, Toshimitsu ^c   Katsumi, Tetsuo ^a   Namiki, Mikio ^b  

^a National Kanazawa Hospital   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c TONAMI GENERAL HOSPITAL   (Japan)

Author keywords

Biochemical recurrence; Japanese general rule; Neoadjuvant therapy; Pathological effect; Prostate cancer

Indexed keywords

CHLORMADINONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LUPRIN; ODYNE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; DRUG EFFECT; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; SCORING SYSTEM; TUMOR BIOPSY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 0042203576     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2003.00640.x     Document Type: Article

References (23)

1. Kypriaunau N, English HF, Issacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 1990; 50: 3748-53.
2. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage; B2 (T2b:NxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J. Urol. 1995; 154: 424-8.
3. Labrie F, Cusan L, Gomes J. Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 1994; 44: 29-37.
4. Cookson MS, Sogani PC, Russo P et al. Pathologic staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: result of a phase II study. Br. J. Urol. 1997; 79: 432-8.
5. Fair WR, Garnick MB. Neoadjuvant therapy prior to radical prostatectomy: pro. Urology 1996; 48: 535-8.
6. Paulson DF. Neoadjuvant therapy prior to radical prostatectomy: con. Urology 1996; 48: 539-40.
7. Fair WR, Cookson MS, Stroumbakis N et al. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997; 49 (Suppl. 3A): 46-55.
8. Klotz LH, Goldenberg SL, Jewett M et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. Urology 1999; 53: 757-63.
9. Gleave ME, LaBianca SE, Goldenberg L, Jones EC, Bruchovsky N, Sullivan L. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: Evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 2000; 56: 289-94.
10. Peller PA, Young DC, Marmaduke DP, Marsh WL, Badalament RA. Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer 1995; 75: 530-8.
11. Partin AW, Kattan MW, Subong ENP et al. Clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997; 277: 1445-51.
12. Murphy WM, Soloway MS, Barrows GH. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 1991; 68: 821-8.
13. Smith DM, Murphy WM. Histologic changes in prostatic carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect): distinction from poor tumor differentiation. Cancer 1994; 73: 1472-7.
14. Armas OA, Aprikian AG, Melamed J et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am. J. Surg. Pathol. 1994; 18: 979-91.
15. Vaillancourt L, Têtu B, Fradet Y et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. Am. J. Surg. Pathol. 1996; 20: 86-93.
16. International Union Against Cancer. Urologic Tumors. Prostate. In: Sobin LH, Wittekind CH (eds). TNM Classification of Malignant Tumours, 5th edn. John Wiley & Sons, New York, 1997; 170-3.
17. Japanese Urological Association the Japanese society of pathology. General Rule for Clinical and Pathological Studies on Prostatic Cancer, 3rd edn. Kanahara, Tokyo, 2001.
18. Kuperian P, Katcher J, Levin H, Zippe C, Klein E. Correlation of clinical and pathologic factors with rising prostate specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996; 48: 249-60.
19. Dillioglugil Ö, Leibman BD, Kattan MW, Seale-Hawkins C, Wheeler TM, Scardino PT. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 1997; 50: 93-9.
20. Reuter VE. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 1997; 49 (Suppl. 3A): 16-22.
21. Van de Voorde WN, Elgamal AA, Van Poppel HP, Verbeken EK, Baert LV, Lauweryns JM. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. Cancer 1994; 74: 3164-75.
22. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Biochemical and pathologic effect of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J. Urol. 1996; 155: 213-9.
23. Köllermann MW, Pantel K, Enzmann T et al. Supersensitive PSA-monitored neoadjuvant hormone treatment of clinically localized prostate cancer: effects on positive margins, tumor detection and epithelial cells in bone marrow. Eur. Urol. 1998; 34: 318-24.